Why Bluejay Diagnostics Shares Are Surging Higher Today


Shares of small-cap penny stock Bluejay Diagnostics, Inc. BJDX are trading higher after the company announced that the FDA has agreed to consider its plan to pursue a De Novo submission for the Symphony IL-6 Test.

Neil Dey, Chief Executive Officer, said “This confirms our belief that the Bluejay Symphony IL-6 Test has the potential to provide an innovative solution to the market. Bluejay continues to advance the Symphony IL-6 Test towards the Company’s anticipated marketing application with the FDA, expected by year-end 2022.”

Bluejay Diagnostics develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States.

Bluejay Diagnostics, Inc. shares were trading about 30% higher at $1.68 per share on Thursday at the time of publication.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksFDAMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!